Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Histidyl-Trna Synthetases
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 13/809,757, filed Apr 29, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,422,539 | Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Histidyl-Trna Synthetases In force · Medium confidence | Atyr Pharma, Inc. | In force | Medium confidence | ||
| US 9,637,730 | Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Histidyl-Trna Synthetases In force · Medium confidence | Atyr Pharma, Inc. | In force | Medium confidence | ||
| US 10,196,628 | Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Histidyl-Trna Synthetases In force · Medium confidence | Atyr Pharma, Inc. | In force | Medium confidence | ||
| US 10,669,533 | Innovative Discovery of Therapeutic, Diagnostic, and Antibody Compositions Related to Protein Fragments of Histidyl-Trna Synthetases In force · Medium confidence | Atyr Pharma, Inc. | In force | Medium confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.